Arbutus Biopharma (ABUS) Misses Q3 EPS by 5c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/22/2026
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Oil price dips to $100 on hopes of US-Iran diplomacy, partial recovery in Saudi exports
- Paramount, Warner Bros jump on report of settlement progress in merger fight
- Investors may be underpricing how far rate hikes could go, Deutsche says
- Pennsylvania measles cases near 800 as outbreak grows
- A timeline of Trump administration moves to weaken endangered species protections
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- SpaceX and Tesla’s AI linkup is getting deeper. Here’s what Morgan Stanley sees
Arbutus Reports Third Quarter 2020 Financial Results and Provides Corporate Update
November 5, 2020 7:30 AM ESTResults from an ongoing Phase 1a/1b clinical trial for Arbutus AB-729, a subcutaneously delivered RNAi agent, in subjects with chronic hepatitis B virus (HBV) infection, to be presented at the upcoming American Association for the Study of Liver Disease (AASLD) Conference
Clinical collaboration with Assembly Biosciences, Inc. established to evaluate Arbutus AB-729 in combination with vebicorvir, Assemblys oral core/capsid inhibitor
AB-836, Arbutus oral capsid inhibitor, remains on track for completion of CTA/IND-enabling studies by the end of 2020
Conference Call and... More
